Oncoinvent invites for Q3 2025 company update in English on Tuesday 4[th] of November at 08:30 AM CEST. The presentation will be broadcasted live on https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. There will be a possibility for Q&A.
Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the “Company”) on 29 October 2025 regarding the completion of the merger between the Company and the former Oncoinvent ASA (reg. no. 995 764 458) (“Oncoinvent”) (the “Merger”).
Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January.
Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and Oncoinvent ASA (“Oncoinvent”) through a statutory triangular merger (the “Merger”), including the announcements made on 4 August 2025 regarding approval of the Merger by the extraordinary general meetings of the two companies. Reference is further made to the stock exchange announcement made on 24 October 2025 regarding key dates for completion of the Merger and the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the “Prospectus”) prepared in connection with the Merger and the contemplated rights issue in the combined company.
Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by BerGenBio ASA (OSE: BGBIO) (“BerGenBio”) and Oncoinvent ASA (OSE: ONCIN) (“Oncoinvent”) regarding the combination of the two companies through a statutory triangular merger (the “Merger”), and the announcements on 4 August 2025 regarding the approval of the merger plan by the extraordinary general meetings of BerGenBio and Oncoinvent, respectively.
New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression
Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced positive final 24-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.